Cabergoline review

Cabergoline is a combination of derived ergot fungi alkaloids that is used to treat Parkinson s disease, as well as some defined hormone problems such as excessive prolactin production. As a direct causative agent, this drug is used to prevent and inhibit progressive breast milk production in lactating mothers, but is not as effective when recently given birth.

Other designation for this drug is as to impede functional output of prolactin producing or causing tumors and also as a hormone regulator for certain types of ovarian diseases.

In a cellular level, the drug inhibits dopamine receptors in the hypothalamus, more specifically in the lactophilic cells, which in turn inhibits the reception of signals in the pituitary gland to release prolactin. The medication of Cabergoline is considered to be an effective alternative to Bromocriptine if the latter is ineffective in treating prolactin production disorders.

Those who have early onset symptoms of Parkinson's disease may benefit from single drug type therapy of Cabergoline. It may also be used to combine with certain drugs such as levodopa or carbidopa for much later stages of Parkinson's.

For other types of use, the drug is also advised and prescribed by physicians as treatment for microprolactinomas or otherwise known as malfunction of the prolactin producing tumors in the pituitary gland. This is highly evident with those patients having hyperactive pituitary glands.

As an alternative for Bromocriptine, it may also be used as treatment of amenorrhea, anovulation, and galactorrhea.

In some unlikely considerations, the Cabergoline drug is also believed to be used to heighten and correct issues pertaining to libido dysfunction and anorgasmia. Bodybuilders have also taken use of the drug's effects as a means to combat the occurrence of gynecomastia, which is a rather common side effect of anabolic steroid medications.

As a monotherapeutic drug for Parkinson's disease, the recommended dosage would be an initial dose of .5-milligram daily, and increased to a dose of 2 to 4 milligram per day. As a combinant drug to levodopa or carbidopa, it could be adjusted to a maximum of 2 to 6 milligram doses.

For cancerous cells and tumors, or perhaps hyperprolactinemic disorders, an initial 0.5-milligram per week may be used and administered, with a gradual increase to 4.5mg per week, as necessary and as prescribed by the physician. Doctor's may modify the actual recommended dosage depending on the certain reaction and situation per patient.

The most common side effect upon taking of the drug is weakness, followed by fatigue or body malaise. In more severe cases, vomiting is evident, with combined headache and dizziness. It is advisable to notify the attending doctor of any unusual things happening after taking the prescription drug.

There are also cases wherein hypertension becomes consistently manifested. Due to the effect of prolactin inhibition, pain in the breast area may be felt as an indirect effect to target tissue.

For pregnant or lactating mothers postpartum, it is highly discouraged to administer this drug unless gravely necessary as it disrupts the normal development of the child with hormonal curbing. Furthermore, the drug is known to be able to pass through milk during breastfeeding and may pose a serious threat to the baby.

Cabergoline has the following structural formula:

Chemical structure of cabergoline

• Molecular formula of cabergoline is C26H37N5O2
Cabergoline available : 0,5mg tablets

Brand name(s): Cabaser, Cabergolina, Cabergolinum, Dostinex

  Your Cabergoline review